640 Memorial Drive
37 articles with Boston Biomedical
Boston Biomedical, Inc. Highlights Phase 1 Data Evaluating Investigational WT1 Cancer Peptide Vaccine DSP-7888 (ombipepimut-S*) in Patients with Advanced Malignancies at SITC 2019
Boston Biomedical, Inc. today announced the presentation of new data from a phase 1 study evaluating DSP-7888, an investigational WT1 cancer peptide vaccine, in patients with advanced malignancies.
Even with a holiday week, July 4, there were a number of clinical trial reports. Here’s a look.
Boston Biomedical, Inc. Announces Update on Phase 3 CanStem111P Study of Napabucasin in Patients with Metastatic Pancreatic Cancer Following Interim Analysis
Boston Biomedical, Inc. announced that the CanStem111P study evaluating the safety and efficacy of investigational agent napabucasin plus weekly nab-paclitaxel with gemcitabine versus weekly nab-paclitaxel with gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma will be discontinued due to futility.
Pancreatic cancer is a particularly difficult cancer to treat, and although there have been advances in treatment, it is still an extremely deadly disease. Here’s a look at some recent news concerning pancreatic cancer.
Boston Biomedical, Inc. Announces the Continuation of the Phase 3 CanStem303C Study of Napabucasin in Patients with Advanced Colorectal Cancer Following Interim Analysis
Boston Biomedical, Inc. announced the continuation of the CanStem303C study evaluating the safety and efficacy of investigational agent napabucasin when given in combination with FOLFIRI with or without bevacizumab in patients with advanced colorectal cancer.
According to the National Cancer Institute (NCI), pancreatic cancer is relatively rare, with about 55,440 cases diagnosed annually, representing about 3.2 percent of new cancer cases. But each year, 44,330 Americans die from the disease, or about 7.3 percent of cancer deaths.
Boston Biomedical, Inc. Highlights Presentations on Investigational Agents Napabucasin and DSP-7888 (ombipepimut-S*) at ASCO 2018
Boston Biomedical, Inc. announced that it will present new research evaluating investigational compound napabucasin in the treatment of multiple cancers, including metastatic pancreatic adenocarcinoma, advanced gastric and gastroesophageal junction adenocarcinoma, and advanced thymoma and thymic carcinoma at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting.
Boston Biomedical Appoints Edgar Braendle, M.D., Ph.D., as Head of Research and Development and Chief Medical Officer
Boston Biomedical today announced the appointment of Edgar Braendle, M.D., Ph.D., to Executive VP, Head of Research and Development and CMO.
Boston Biomedical Announces Orphan Drug Designation By FDA For Investigational WT1 Cancer Peptide Vaccine DSP-7888 In Brain Cancer
Boston Biomedical Announces Orphan Drug Designation By FDA For Investigational WT1 Cancer Peptide Vaccine DSP-7888 In Myelodysplastic Syndrome
Boston Biomedical Presents Data For Investigational Cancer Stemness Inhibitor Napabucasin In Metastatic Colorectal And Pancreatic Cancer At ESMO GI 2017
Boston Biomedical Presents Data Suggesting Anti-Cancer Activity Of Investigational Stemness Inhibitor Napabucasin In Seven Tumor Types At ASCO 2017
Boston Biomedical Broadens Its Portfolio With A Focus On Strategic Technology Development As Stefan Schreck, PhD Joins The Senior Management Team
Boston Biomedical Presents New Preclinical Data At AACR 2017 Highlighting The Potential Role Of Cancer Stemness Inhibition
Boston Biomedical Initiates Canstem111p: A Global Phase III Study Investigating Cancer Stemness Inhibitor Napabucasin In Patients With Metastatic Pancreatic Cancer
Boston Biomedical Announces First Clinical Data For Investigational WT1 Cancer Peptide Vaccine, DSP-7888, At American Society of Hematology Annual Meeting & Exposition
Boston Biomedical Initiates Canstem303c: A Global Phase III Study Investigating Cancer Stemness Inhibitor Napabucasin In Patients With Pretreated Advanced Colorectal Cancer